457 related articles for article (PubMed ID: 9208339)
1. Pharmacokinetics of incadronate, a new bisphosphonate, in healthy volunteers and patients with malignancy-associated hypercalcemia.
Usui T; Oiso Y; Tomita A; Ogata E; Uchida T; Ikeda K; Watanabe T; Higuchi S
Int J Clin Pharmacol Ther; 1997 Jun; 35(6):239-44. PubMed ID: 9208339
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of YM175, a new bisphosphonate, in rats and dogs.
Usui T; Watanabe T; Higuchi S
Drug Metab Dispos; 1995 Nov; 23(11):1214-9. PubMed ID: 8591721
[TBL] [Abstract][Full Text] [Related]
3. Comparison of pharmacokinetics of clodronate after single and repeated doses.
Ylitalo P; Holli K; Mönkkönen J; Elo HA; Juhakoski A; Liukko-Sipi S; Ylitalo R
Int J Clin Pharmacol Ther; 1999 Jun; 37(6):294-300. PubMed ID: 10395121
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and urinary excretion of eprosartan in Chinese healthy volunteers of different gender.
Xu HR; Chen WL; Li XN; Liu GY; Chu NN; Yu C
Pharmazie; 2007 Oct; 62(10):782-4. PubMed ID: 18236785
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers.
Lin CC; Philips L; Xu C; Yeh LT
J Clin Pharmacol; 2004 Mar; 44(3):265-75. PubMed ID: 14973309
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of disodium clodronate after daily intravenous infusions during five consecutive days.
Hanhijärvi H; Elomaa I; Karlsson M; Lauren L
Int J Clin Pharmacol Ther Toxicol; 1989 Dec; 27(12):602-6. PubMed ID: 2533182
[TBL] [Abstract][Full Text] [Related]
8. Dose linearity and other pharmacokinetics of cefodizime after single-dose intravenous administration.
Dagrosa EE; Hajdú P; Malerczyk V; de Looze S; Seeger K; Grötsch H
Clin Ther; 1987; 10(1):18-31. PubMed ID: 3450392
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of isepamicin.
Barr WH; Colucci R; Radwanski E; Zampaglione N; Cutler D; Lin CC; Elliott M; Affrime MB
J Chemother; 1995 Jun; 7 Suppl 2():53-61. PubMed ID: 8622111
[TBL] [Abstract][Full Text] [Related]
10. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers.
Chen TL; Vogelsang GB; Petty BG; Brundrett RB; Noe DA; Santos GW; Colvin OM
Drug Metab Dispos; 1989; 17(4):402-5. PubMed ID: 2571480
[TBL] [Abstract][Full Text] [Related]
11. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
Perucca E; Cloyd J; Critchley D; Fuseau E
Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of fleroxacin in renal impairment.
Weidekamm E
Am J Med; 1993 Mar; 94(3A):70S-74S. PubMed ID: 8452185
[TBL] [Abstract][Full Text] [Related]
13. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
14. Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects.
Hoffmann M; DeMaio W; Jordan RA; Talaat R; Harper D; Speth J; Scatina J
Drug Metab Dispos; 2007 Sep; 35(9):1543-53. PubMed ID: 17537869
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man.
Boneu B; Necciari J; Cariou R; Sié P; Gabaig AM; Kieffer G; Dickinson J; Lamond G; Moelker H; Mant T
Thromb Haemost; 1995 Dec; 74(6):1468-73. PubMed ID: 8772222
[TBL] [Abstract][Full Text] [Related]
16. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects.
Wong SL; Barriere SL; Kitt MM; Goldberg MR
J Antimicrob Chemother; 2008 Oct; 62(4):780-3. PubMed ID: 18586659
[TBL] [Abstract][Full Text] [Related]
17. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
Bergman A; Ebel D; Liu F; Stone J; Wang A; Zeng W; Chen L; Dilzer S; Lasseter K; Herman G; Wagner J; Krishna R
Biopharm Drug Dispos; 2007 Sep; 28(6):315-22. PubMed ID: 17575559
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose.
Wagenlehner FM; Kinzig-Schippers M; Tischmeyer U; Wagenlehner C; Sörgel F; Dalhoff A; Naber KG
Int J Antimicrob Agents; 2006 Jan; 27(1):7-14. PubMed ID: 16343856
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of azlocillin in healthy subjects.
Leroy A; Humbert G; Fillastre JP
Scand J Infect Dis Suppl; 1981; 29():49-54. PubMed ID: 6947405
[TBL] [Abstract][Full Text] [Related]
20. Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs.
Baldwin JR; Lewis RC; Phillips BA; Overmyer SK; Hatfield NZ; Narang PK
Biopharm Drug Dispos; 1996 Aug; 17(6):541-50. PubMed ID: 8866044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
